Please assess the completion status of the following clinical trial:

Trial Title: Systolic Blood Pressure Intervention Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 50 years old~Systolic blood pressure of~* 130 - 180 mm Hg on 0 or 1 medication~* 130 - 170 mm Hg on up to 2 medications~* 130 - 160 mm Hg on up to 3 medications~* 130 - 150 mm Hg on up to 4 medications~Risk (one or more of the following)~1. Presence of clinical or subclinical cardiovascular disease other than stroke~2. CKD, defined as eGFR 20 - 59 ml/min/1.73m2~3. A Framingham Risk Score for 10-year CVD risk ≥ 15%~4. Age greater than 75 years~Exclusion Criteria:~* An indication for a specific BP lowering medication that the person is not taking and the person has not been documented to be intolerant of the medication class.~* Known secondary cause of hypertension that causes concern regarding safety of the protocol.~* One minute standing SBP \< 110 mm Hg.~* Proteinuria in the following ranges (based on a measurement within the past 6 months)~  * 24 hour urinary protein excretion ≥1 g/day, or~ * 24 hour urinary albumin excretion ≥ 600 mg/day, or~ * spot urine protein/creatinine ratio ≥ 1 g/g creatinine, or~ * spot urine albumin/creatinine ratio ≥ 600 mg/g creatinine, or~ * urine dipstick ≥ 2+ protein~* Arm circumference too large or small to allow accurate blood pressure measurement with available devices~* Diabetes mellitus,~* History of stroke (not CE or stenting)~* Diagnosis of polycystic kidney disease~* Glomerulonephritis treated with or likely to be treated with immunosuppressive therapy~* eGFR \< 20 ml/min /1.73m2 or end-stage renal disease (ESRD)~* Cardiovascular event or procedure (as defined above as clinical CVD for study entry) or hospitalization for unstable angina within last 3 months~* Symptomatic heart failure within the past 6 months or left ventricular ejection fraction (by any method) \< 35%~* A medical condition likely to limit survival to less than 3 years or a malignancy other than non-melanoma skin cancer within the last 2 years~* Any factors judged by the clinic team to be likely to limit adherence to interventions.~* Failure to obtain informed consent from participant~* Currently participating in another clinical trial (intervention study). Note: Patient must wait until the completion of his/her activities or the completion of the other trial before being screened for SPRINT.~* Living in the same household as an already randomized SPRINT participant~* Any organ transplant~* Unintentional weight loss \> 10% in last 6 months~* Pregnancy, currently trying to become pregnant, or of child-bearing potential and not using birth control.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Intensive Control of SBP (Type: EXPERIMENTAL): Participants randomized into the Intensive BP arm will have a goal of SBP \<120 mm Hg. 2-drug therapy initiated in most Intensive participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP \<120 mm Hg; at periodic milepost visits: addition of another drug required if not at goal.
- Standard Control of SBP (Type: ACTIVE_COMPARATOR): Participants randomized into the Standard arm will have a goal of SBP \<140 mm Hg. Intensify therapy if SBP ≥160 mm Hg @ 1 visit; ≥140 mm Hg @ 2 consecutive visits; Down-titration if SBP \<130 mm Hg @ 1 visit; \<135 mm Hg @ 2 consecutive visits

Based on this trial design, predict the completion outcome and termination type (if applicable).